Chimeric autoantibody receptor T cells clonally eliminate B cells producing autoantibodies against IFN-γ
- 9 May 2025
- journal article
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 10 (107) , eadm8186
Abstract
Neutralizing anti–interferon-γ (IFN-γ) autoantibodies (nAIGAs) impair IFN-γ–mediated immunity, predisposing patients with nAIGAs to infection by nontuberculous mycobacteria, Talaromyces marneffei , and other intracellular pathogens. Current clinical management relies on continuous antimicrobial therapy, with no treatment offering sustained benefits. Here, we developed human chimeric autoantibody receptor (CAAR) T cells targeting autoreactive B cells expressing nAIGA B cell receptors (BCRs) using an IFN-γ receptor–irresponsive IFN-γ variant as bait. By exploiting a mouse model of nAIGA BCR-expressing B cell leukemia, we found that IFN-γ CAAR T cells lack off-target toxicity, including IFN-γ receptor cross-reactive toxicity and Fc-redirected toxicity. IFN-γ CAAR T cells substantially reduced circulating AIGAs secreted from target cells in vivo. Further, IFN-γ CAAR T cells effectively eliminated autoreactive B cells in ex vivo cultures of peripheral blood mononuclear cells from patients with nAIGAs. Together, these results demonstrate that IFN-γ CAAR T cells may be a promising strategy to ameliorate nAIGA-associated infections by eliminating autoreactive B cells.Keywords
This publication has 43 references indexed in Scilit:
- Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosisCell, 2024
- Chimeric autoantibody receptor T cells deplete NMDA receptor-specific B cellsCell, 2023
- Analysis of Rituximab Use, Time Between Rituximab and SARS-CoV-2 Vaccination, and COVID-19 Hospitalization or Death in Patients With Multiple SclerosisJAMA Network Open, 2022
- Plasma Exchange to Rescue Patients with Autoantibodies Against Type I Interferons and Life-Threatening COVID-19 PneumoniaJournal of Clinical Immunology, 2021
- Emapalumab: First Global ApprovalDrugs, 2019
- Chylous ascites, anti-interferon-gamma autoantibody, and angioimmunoblastic T-cell lymphoma: a rare but intriguing connection over Mycobacterium aviumMedical Microbiology and Immunology, 2018
- Rituximab Restores IFN-γ-STAT1 Function and Ameliorates Disseminated Mycobacterium avium Infection in a Patient with Anti-Interferon-γ AutoantibodyJournal of Clinical Immunology, 2017
- Pharmacokinetic and Pharmacodynamic Relationship of AMG 811, An Anti-IFN-γ IgG1 Monoclonal Antibody, in Patients with Systemic Lupus ErythematosusPharmaceutical Research, 2014
- Clonal dissection of the human memory B‐cell repertoire following infection and vaccinationEuropean Journal of Immunology, 2009
- Structural elements required for receptor recognition of human interferon-gammaPharmacology & Therapeutics, 1994